A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer

Urol Oncol. 2020 Jun;38(6):606-607. doi: 10.1016/j.urolonc.2020.03.027. Epub 2020 Apr 15.

Authors

Wojciech Krajewski¹, Łukasz Nowak², Sławomir Poletajew³

Affiliations

¹ Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. Electronic address: wk@softstar.pl.
² Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland.
³ Second Department of Urology, Centre of Medical Postgraduate Education, Warsaw, Poland.

PMID: 32303408
DOI: 10.1016/j.urolonc.2020.03.027

No abstract available

Publication types

Letter
Comment

MeSH terms

Administration, Intravesical
Antineoplastic Agents*
BCG Vaccine
Humans
Prospective Studies
Urinary Bladder Neoplasms*

Substances

Antineoplastic Agents
BCG Vaccine